Richard Scott Struthers - 28 Feb 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
28 Feb 2022
Transactions value $
$0
Form type
4
Filing time
02 Mar 2022, 20:00:50 UTC
Previous filing
09 Sep 2021
Next filing
07 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Award $0 +53.4K +1335% $0.00 57.4K 28 Feb 2022 Direct F1
holding CRNX Common Stock 1K 28 Feb 2022 By Spouse
holding CRNX Common Stock 891K 28 Feb 2022 By Family Trust 1
holding CRNX Common Stock 90K 28 Feb 2022 By Family Trust 2
holding CRNX Common Stock 90K 28 Feb 2022 By Family Trust 3
holding CRNX Common Stock 90K 28 Feb 2022 By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Common Stock (right to buy) Award $0 +249K $0.00 249K 28 Feb 2022 Common Stock 249K $20.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023..
F2 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.